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Abstract
Hepatitis C virus (HCV) is an important human pathogen causing 400 000 chronic liver disease- related deaths annually. Until 
recently, the majority of laboratory- based investigations into the biology of HCV have focused on the genotype 2 isolate, JFH-1, 
involving replicons and infectious cell culture systems. However, genotype 2 is one of eight major genotypes of HCV and there is 
great sequence variation among these genotypes (>30 % nucleotide divergence). In this regard, genotype 3 is the second most 
common genotype and accounts for 30 % of global HCV cases. Further, genotype 3 is associated with both high levels of inher-
ent resistance to direct- acting antiviral (DAA) therapy, and a more rapid progression to chronic liver diseases. Neither of these 
two attributes are fully understood, thus robust genotype 3 culture systems to unravel viral replication are required. Here we 
describe the generation of robust genotype 3 sub- genomic replicons (SGRs) based on the adapted HCV NS3- NS5B replicase 
from the DBN3a cell culture infectious clone. Such infectious cell culture- adaptive mutations could potentially promote the 
development of robust SGRs for other HCV strains and genotypes. The novel genotype 3 SGRs have been used both transiently 
and to establish stable SGR- harbouring cell lines. We show that these resources can be used to investigate aspects of genotype 
3 biology, including NS5A function and DAA resistance. They will be useful tools for these studies, circumventing the need to 
work under the biosafety level 3 (BSL3) containment required in many countries.
INTRODUCTION
Hepatitis C virus (HCV) infects 70 million individuals world-
wide. In 85 % of the 2 million annual new cases, infection leads 
to chronic hepatitis, eventually causing liver diseases such 
as fibrosis, cirrhosis and hepatocellular carcinoma (HCC). 
HCV has a positive- strand RNA genome and is the most 
variable human virus, classified into eight genotypes (GTs) 
and exhibiting >30 % nucleotide sequence divergence, with 
each GT being further divided into subtypes [1–3]. GT3 is 
the second most common GT (after GT1) and accounts for 
30 % of global HCV cases [4, 5]. The burden of GT3 infection 
falls disproportionately on low- to- middle income countries 
(LMICs); in particular, 70 % of HCV infections in Pakistan, 
India and Thailand are GT3 [6], and it is believed that the 
global dissemination of GT3 is in part due to population 
migration from these countries. Consistent with this, GT3 is 
highly prevalent in the UK (47 % of HCV cases), and in other 
parts of Western Europe.
HCV GT3 is of interest as it presents higher levels of resist-
ance to the direct- acting antivirals (DAAs) that are now 
extensively used to treat HCV infection; in particular, GT3 
isolates are more resistant to the class of DAAs that target 
NS5A [e.g. the first in class drug daclatasvir (DCV)] [7]. In 
addition, compared to other GTs, GT3 infection is associ-
ated with a higher incidence of insulin resistance and steatosis 
(fatty liver), leading to a more rapid progression to chronic 
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liver disease [4]. The reasons underpinning these two unique 
characteristics remain to be fully elucidated. In this context, 
the study of GT3 biology would be greatly facilitated by the 
development of robust in vitro replication systems, both 
infectious clones and sub- genomic replicons (SGRs). To 
this end, two groups established GT3a SGRs from serum- 
derived full- length cDNA clones (S310 and S52) [8, 9]. In 
both cases. passage of G418- resistant colonies resulted in the 
acquisition of cell culture- adaptive mutations that enhanced 
replication. Despite these mutations, replication rates for 
these SGRs remained low compared to the ‘gold standard’ 
GT2a JFH-1- derived SGRs [10], perhaps reflecting the lack 
of in vitro infectivity of the full- length clones used for their 
creation [8, 11].
A significant breakthrough was the development of the 
DBN3a cell culture infectious clone (DBN3acc) – the introduc-
tion of 17 substitutions across the genome resulted in levels 
of infectivity that were comparable to those for JFH-1 [12]. 
Here we describe the further development of SGRs derived 
from DBN3acc and their potential use for the study of GT3 
DAA resistance and virus–host interactions.
METHODS
Cell culture
Huh7.5 cells were cultured in Dulbecco’s modified Eagle’s 
medium (Sigma) supplemented with 10 % (v/v) foetal bovine 
serum (FBS), 100 IU ml−1 penicillin, 100 µg ml−1 streptomycin 
and 1 % (v/v) non- essential amino acids (Lonza) in a humidi-
fied incubator at 37 °C with 5 % CO2. An Huh7.5 cell line 
harbouring the SGR- neo- DBN3a replicon was generated by 
electroporation with in vitro RNA transcripts of SGR- neo- 
DBN3a. At 48 h post- electroporation (p.e.) cells were selected 
with G418 (700 µg ml−1) until cell colonies were visible. Colo-
nies were then expanded and maintained in the presence of 
G418 at 400 µg ml−1.
Generation of SGR constructs
An SGR- DBN3a construct without reporter was created 
using a synthetic gene string (Genewiz) covering the region 
from an unique NruI site within the 5′ UTR to an unique 
BsiWI site within NS3 of DBN3acc. This gene string encoded 
a truncated core region to permit functional IRES transla-
tion followed by two new unique restriction sites, SnaBI 
and MluI, and an EMCV IRES to drive the translation of the 
downstream HCV polyprotein NS3- NS5B. The SnaBI and 
MluI sites were used to introduce a firefly luciferase gene 
engineered to contain reduced CpG and UpA dinucleotide 
frequencies [13], neomycin phosphotransferase or eGFP 
reporters.
The SGR- eGFP- JFH-1 construct was made by the removal of 
the luciferase reporter gene from the SGR- luc- JFH-1 plasmid 
[10] using flanking PmeI and BglII restriction sites. The eGFP 
reporter was then generated by PCR amplification incorpo-
rating PmeI and BglII sites.
In vitro RNA transcription
SGR constructs were transcribed in vitro using 1 µg of 
linearized and purified DNA template and the RiboMax 
T7 Transcription kit following manufacturer’s protocol 
(Promega). Transcribed RNA was purified using RNA Clean 
and Concentrator-25 (Zymogen).
Luciferase assays
Huh7.5 cells were used to study replicon replication. 
Cells were washed twice in ice cold phosphate- buffered 
saline (PBS) before electroporation of 4×106 cells in PBS 
with 2 µg of RNA as described previously [14]. Cells were 
resuspended in complete media and seeded onto 96- well 
plates at 3×104 cells/well. At 4, 24, 48 and 72 h p.e. cells 
were harvested by lysis with 50 µl of passive lysis buffer 
(Promega). Luciferase activity was determined on a BMG 
plate reader by the addition of 50 µl of luciferase assay 
reagent (Promega) to 50 µl of lysate.
DAA assays
Sensitivity to DAAs was ascertained by electroporation 
of SGR- luc- DBN3a or SGR- luc- JFH-1 (original or Y93H 
mutants) into Huh7.5 cells as described above. At 4 h p.e. 
media were changed and replaced with complete media 
containing daclatasvir (DCV), cyclosporin A (CsA), 
velpatasvir (VEL) or sofosbuvir (SOF) in a titrating concen-
tration as indicated. Electroporated cells were incubated for 
72 h before lysis and luciferase activity was determined as 
described above.
GFP replicon assays
Huh7.5 cells were seeded onto 24 well plates at 1×104 cells 
per well. RNA transcripts of SGR- eGFP- DBN3a or SGR- 
eGFP- JFH-1 were prepared and 1 µg of RNA was transfected 
per well using Lipofectamine 2000 following the manufactur-
er’s protocol (Thermo Fisher). Four hours post- transfection, 
the medium was removed and replaced with complete 
medium before incubation in an IncuCyte ZOOM.
Western blotting
Huh7 cells harbouring SGR- feo- JFH-1 or Huh7.5 cells 
harbouring SGR- neo- DBN3a were lysed using Glasgow 
lysis buffer (1 % Triton X-100, 120 mM KCl, 30 mM NaCl, 
5 mM MgCl2, 10 % glycerol (v/v) and 10 mM PIPES, pH 
7.2) with protease inhibitors and phosphatase inhibitors 
added. Proteins were separated by electrophoresis on a 7.5 % 
SDS- PAGE gel, and following electrophoresis, proteins were 
transferred onto PVDF membrane and blocked with 50 % 
(v/v) Odyssey blocking buffer (LiCor) in Tris- buffered 
saline (TBS). The membrane was then incubated with 
primary antibody as labelled, sheep anti- NS5A [15], rabbit 
anti- pS225 [16] or rabbit anti- pS232 [17] at 4 °C overnight. 
After washing with TBS, membranes were incubated with 
fluorescently labelled anti- sheep (800 nm) and anti- rabbit 
(680 nm) secondary antibodies for 1 h at room temperature. 
Unbound secondary antibody was removed, and membrane 
imaged on a LiCor Odyssey Sa fluorescent imager.
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Immunofluorescent microscopy
Huh7.5 cells harbouring SGR- neo- DBN3a were seeded at 
1×105 cells per well onto a 24- well plate. Cells were left to 
adhere before fixation using 4 % paraformaldehyde in dH20 
and permeabilized with 0.1 % (v/v) Triton X-100 (Sigma) for 
7 min. Coverslips were washed twice in PBS and primary 
sheep anti- NS5A was applied in 10 % (v/v) FBS in PBS and 
incubated for 2 h at room temperature. Unbound primary 
antibody was removed before the addition of donkey anti- 
sheep Alexa Fluor 594 nm. Secondary antibody was incubated 
in the dark for 1 h and excess was removed by washing with 
PBS. Cells were then imaged in the Incucyte ZOOM.
For confocal microscopy cells were seeded onto glass cover-
slips and left to adhere for 24 h. Cells were fixed and stained 
with primary antibody as above. Unbound primary antibody 
was removed before the addition of donkey anti- sheep Alexa 
Fluor 594 nm. Secondary antibody was incubated in the 
dark for 1 h and excess was removed by washing with PBS. 
Coverslips were mounted on a microscope slide with ProLong 
gold antifade (Invitrogen). Confocal microscopy images were 
acquired using a Zeiss LSM 880 microscope.
RESULTS
DBN3a-derived SGRs replicate efficiently in Huh7.5 
cells
To provide a broad range of potential applications we gener-
ated HCV SGRs containing a panel of different reporters: a 
firefly luciferase gene engineered to contain reduced CpG 
and UpA dinucleotide frequencies [13], neomycin phos-
photransferase and eGFP. These reporters were fused at the 
N- terminus to the first 12 residues of the DBN3a core protein 
(ΔCore) to ensure that full IRES activity was retained. Expres-
sion of the DBN3a NS3- NS5B proteins with infectious cell 
culture- adaptive substitutions was driven by a second IRES 
derived from EMCV (Fig. 1). As a negative control we gener-
ated a mutant in which the active site of the NS5B RdRp was 
mutated from GDD to GNN.
We first evaluated the transient replication of the SGR- luc- 
DBN3a in Huh7.5 cells and compared it to two other SGRs. 
Firstly, the GT3a isolate S52 (AII), which contained three 
culture- adaptive mutations (T1056A, T1429I and S2204I) 
[9, 18], referred to as S52 hereafter. Secondly, the GT2a 
isolate JFH-1 [10], which did not contain any culture- adaptive 
mutations. Polymerase- inactive (GNN) mutants of each of 
these SGRs were included in the assay. As shown in Fig. 2a, 
SGR- luc- JFH-1 replicated robustly, as expected, exhibiting 
a >100- fold increase in luciferase expression over 48 h, 
whereas replication of SGR- luc- S52 was almost undetectable, 
as observed previously [18]. Reassuringly, SGR- luc- DBN3a 
replicated efficiently, although it exhibited a delay compared 
to JFH-1, with reduced luciferase expression at 24 h compared 
to the increase seen in JFH-1. However, DBN3a did show a 
subsequent increase in expression at 48 and 72 h, reaching 
an approximately 100- fold increase in luciferase expression.
Using an SGR containing an eGFP reporter (SGR- eGFP- 
DBN3a), we were able to derive real- time kinetic data for 
the rate of replication of DBN3a using an IncuCyte ZOOM, 
an automated fluorescent microscope situated within an 
incubator (Fig. 2b). This approach has been used extensively 
for analysis of FMDV replication [19]. Using this real- time 
imaging, replication was assessed by the number of eGFP- 
positive cells, and we observed a similar delay in SGR- eGFP- 
DBN3a replication compared to SGR- eGFP- JFH-1. The latter 
Fig. 1. Structure of the DBN3a infectious clone and bicistronic SGRs. (a) Genome of the DBN3a
cc
 infectious clone with yellow circles 
indicating sites of mutation to enhance virus replication and propagation [12]. (b) Schematic of the DBN3a SGR: core, E1, E2, p7 and NS2 
coding sequences have been removed, leaving only the 5′ end of the core sequence, coding for the N- terminal 12 amino acids. (ΔCore). 
The reporter (CpG/UpA- low firefly luciferase, neomycin phosphotransferase or eGFP) is thus expressed as a fusion with the N- terminus 
of core and is under the translational control of the HCV IRES. The HCV replicase, NS3- NS5B with DBN3a
cc
 adaptive mutations, is under 
the translational control of the EMCV IRES.
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showed detectable replication from 12 h p.e., increasing to a 
peak at 48 h. In contrast, no eGFP- positive cells were detected 
for SGR- eGFP- DBN3a until approx. 30 h p.e., peaking at 90 h, 
and declining thereafter. As expected, the polymerase- inactive 
mutants failed to accumulate eGFP positivity. Representative 
fluorescence images of the electroporated cells confirmed 
the similar levels of eGFP fluorescence at either 24 h p.e. for 
JFH-1 and 72 h p.e. for DBN3a (Fig. 2c). The sensitivity of the 
IncuCyte ZOOM was not sufficient to detect input translation 
from either JFH-1 or DBN3a constructs.
Evaluation of NS5A expression and phosphorylation
We also established a stable Huh7.5 cell line harbouring 
SGR- neo- DBN3a by selection with G418. As expected, 
immunofluorescence with an anti- NS5A antiserum revealed 
extensive cytoplasmic staining in the selected cell population 
(Fig.  3a). Confocal immunofluorescence microscopy was 
used to compare the distribution of NS5A with that observed 
in cells harbouring SGR- feo- JFH-1 [20] (Fig. 3b). In both cell 
populations NS5A exhibited punctate distribution, but it is 
noteworthy that DBN3a NS5A also showed a more diffuse 
cytoplasmic localization. This cell line will facilitate a more 
detailed analysis of the sub- cellular distribution of DBN3a 
NS5A in the context of the SGR, in comparison to both 
DBN3acc- infected cells and other GTs (e.g. JFH-1).
We then used Western blotting to investigate the apparent 
molecular weight and potential for phosphorylation of 
DBN3a NS5A. In comparison to JFH-1, DBN3a NS5A was 
smaller (Fig. 4a, b, top panels), likely due to the presence of 
an 18 amino acid insertion near the C- terminus of JFH-1 
NS5A [21]. Lysates from SGR- neo- JFH-1- harbouring cells 
showed the expected doublet representing basally and hyper- 
phosphorylated forms of NS5A at an equal intensity. We [18], 
and others [22], had previously shown that S52 only exhibited 
a single NS5A species [18]; this was the case both for the 
culture- adapted S52 [9], which contained the S2204I substitu-
tion, but also for wild- type S52, which maintained the phos-
phorylatable S2204 residue. This was perplexing, as S2204I 
was previously shown to abrogate hyper- phosphorylation in 
genotype 1b [23]. Unlike S52, DBN3a did not contain the 
S2204I substitution [which corresponds to S232 within the 
serine- rich low- complexity sequence I (LCSI)] and should 
therefore be able to undergo hyper- phosphorylation. Inter-
estingly, DBN3a NS5A did exhibit the expected two bands 
corresponding to basally and hyper- phosphorylated species, 
Fig. 2. Transient replication of DBN3a- derived SGRs. (a) Huh7.5 cells 
were electroporated with in vitro transcripts of JFH-1 [10], S52 [9, 18] 
and DBN3a SGRs containing a CpG/UpA low luciferase, and replication 
was monitored by measuring the production of luciferase at 4, 24, 48 
and 72 h p.e. GND/GNN: polymerase- inactive negative controls. n=3, 
error bars represent sem. (b) JFH-1 and DBN3a SGRs containing an 
eGFP reporter were transfected into Huh7.5 cells with corresponding 
GND/GNN- negative controls. Replication was monitored hourly for 96 h 
by measuring eGFP expression using an IncuCyte Zoom. n=2, error bars 
represent sem. (c) Images of JFH-1 and DBN3a eGFP SGR- transfected 
cells at 24 or 72 h p.e., respectively.
Fig. 3. Sub- cellular localization of JFH-1 and DBN3a NS5A. (a) Huh7.5 
cells were electroporated with SGR- neo- DBN3a RNA. SGR- harbouring 
cells were selected using G418. Cells were stained with an antibody 
to NS5A and visualized using immunofluorescent microscopy. (b) SGR- 
feo- JFH-1- or SGR- neo- DBN3a- harbouring cells were stained with an 
antibody to NS5A and visualized with confocal microscopy.
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however, compared to JFH-1, the ratio of hyper : basally 
phosphorylated species was much lower. To investigate this 
further, we used antisera specific for NS5A phosphorylated at 
either S225 [16] or S232 [17]. These antisera had been shown 
to detect hyper- phosphorylated NS5A only, consistent with 
hierarchical phosphorylation of serine residues within LCSI. 
As shown in Fig. 4a, b, DBN3a NS5A was reactive with both 
antisera, demonstrating the presence of both pS225 and pS232. 
We conclude that DBN3a NS5A is hyper- phosphorylated 
within LCSI, resulting in a change in apparent mobility, as 
seen for JFH-1, but that the proportion of DBN3a NS5A that 
is hyper- phosphorylated is lower than for JFH-1.
Use of the DBN3a SGRs for analysis of DAA 
resistance
We proceeded to use the SGR- luc- DBN3a construct to 
evaluate the effect of DAAs on DBN3a genome replication. To 
do this we first generated two derivatives in which previously 
characterized resistance- associated substitutions (RASs) were 
engineered into NS5A. The first of these was Y93H, shown to 
be the predominant RAS in most genotypes, including GT3 
[24, 25]. Another RAS that confers potent resistance to DAAs 
and is associated with treatment failure is a deletion of proline 
32 (ΔP32). However, although this RAS has been reported 
in GT1 [26, 27], it has not been detected in patients with 
GT3 infection. As in vitro analysis of ΔP32 in the context of 
a chimeric GT2b/2a (JFH-1) virus demonstrated that it was 
unable to propagate [28], we reasoned that this might also be 
the case for this RAS in GT3. We therefore tested this using the 
SGR system. As shown (Fig. 5), introduction of Y93H showed 
a small but significant decrease in replication, reflecting data 
previously published for this mutation when introduced into 
both JFH-1 virus and replicons [29]. Introducing ΔP32 into 
the DBN3a replicon exhibited a significant impairment of 
replication, although replication was still occurring, as can 
be seen by the small increase in luciferase production at 72 h. 
Due to the impact of ΔP32 on replication, this mutant was 
not carried forward for DAA sensitivity assays.
SGR- luc- DBN3a and the Y93H variant were used to ascer-
tain the sensitivity of this GT3 strain to NS5A- specific DAAs 
that have been commonly used for treatment of GT3 infec-
tions (Fig. 6). SGR- luc- JFH-1 was used alongside these as a 
comparison. Velpatasvir (VEL) has largely superseded DCV 
as one of the NS5A DAAs of choice for treatment of GT3 
infections [in combination with an NS5B inhibitor sofosbuvir 
(SOF)]. Therefore, as expected, the original SGR- luc- DBN3a 
was more sensitive to VEL than DCV (EC50 1.3 pM vs 37 pM; 
Table 1). The Y93H RAS resulted in the acquisition of a high 
level of resistance to both compounds – for DCV a ~4000- 
fold increase in resistance (EC50 156 nM) was observed, and 
for VEL a 90- fold increase (EC50 118 pM) was observed. To 
confirm that this resistance was specific to the NS5A DAAs, 
we also evaluated the responses of the original and Y93H 
SGR to the NS5B DAA SOF and cyclosporin A (CsA, an 
inhibitor of the cellular peptidyl prolyl isomerase cyclophilin 
family – previously shown to be required for HCV genome 
replication). Y93H had no effect on the EC50 for either of these 
compounds. In comparison to JFH-1, the original DBN3a was 
10- fold more sensitive to VEL but had similar EC50 values for 
the other inhibitors. Of note, the SGR- luc- DBN3a was more 
sensitive to all DAAs in comparison to the infectious clone 
(DBN3acc). The latter exhibited an EC50 of 885 nM (SOF), 345 
pM (DCV) and 24 pM (VEL) [12].
DISCUSSION
The objective of this work was to generate a robust sub- 
genomic replicon system for GT3 HCV that would facilitate 
studies of both viral genome replication and DAA resistance, 
without the need for the biosafety level 3 (BSL3) contain-
ment facilities required in many countries, including the 
UK. Although two GT3a SGR constructs were developed 
Fig. 5. Replication of SGR- luc- DBN3a with resistance- associated 
substitutions (RAS). Huh7.5 cells were electroporated with in vitro- 
transcribed SGR- luc- DBN3a RNA with either the RAS Y93H or an in- 
frame deletion of proline 32 (ΔP32). Luciferase levels were measured 
at the indicated times and compared to mock, original and NS5B- GNN 
controls. n=3, error bars represent sem. **P <0.01, ***P <0.001 for 72 h 
p.e. values compared to original.
Fig. 4. Phosphorylation of DBN3a NS5A. Lysates of Huh7 or Huh7.5 
cells stably harbouring either SGR- feo- JFH-1 or SGR- neo- DBN3a were 
probed using a sheep polyclonal antiserum to detect total NS5A (red), 
together with phospho- specific antibodies to pS225 (a) or pS232 (b) 
(green signal). NS5A species are identified by either red dots (basally 
phosphorylated) or green dots (hyper- phosphorylated). Naïve Huh7.5 
cells were included as a control.
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previously [8, 9], these showed very limited replication 
capacity and replication of these SGRs could only be detected 
in stable SGR- harbouring Huh7 cells by qRT- PCR. Detec-
tion of genome replication using derivatives of S52 with a 
luciferase reporter was subsequently demonstrated [13], but 
the levels of luciferase declined by 48 h p.e. and only returned 
to input values by 96 h p.e. In contrast, the DBN3a- derived 
SGR containing a low- CpG/UpA- luciferase reporter that we 
Fig. 6. Response of SGR- luc- DBN3a to antiviral chemotherapeutics. Huh7.5 cells were electroporated with in vitro- transcribed SGR- 
luc- JFH-1 or SGR- luc- DBN3a (original or Y93H) RNA. Compounds were added at the indicated concentrations. Luciferase levels were 
measured at 72 h p.e. and the effective concentration 50 % (EC
50
) values were calculated using GraphPad Prism. n=3, error bars represent 
sem. DCV, daclatasvir; VEL, velpatasvir; SOF, sofosbuvir; CsA, cyclosporin A.
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developed in this study exhibited an approximately 100- fold 
increase in luciferase values by 48 h p.e. (Fig. 2a). This was 
almost as efficient as the gold standard GT2a JFH-1 SGR. 
Although SGR- luc- DBN3a replicated efficiently, we did 
observe a significant lag when compared to JFH-1 (Fig. 2a). 
This was not dependent on the reporter, as it was also observed 
with an eGFP reporter assayed kinetically using the IncuCyte 
ZOOM (Fig. 2b). An advantage of this system is the ability 
to monitor the relative rates of replication – this also showed 
that, after the lag, DBN3a replication was noticeably slower 
than JFH-1. However, it should be noted that the SGR assay 
is an indirect measurement of genome replication as the read-
 out directly measures reporter translation. It will be of interest 
to investigate the reasons underpinning this lag, as it may 
provide insights into potential biological differences between 
GT3 and other GTs. The SGR constructs generated here will 
be of great utility in such studies.
Importantly, our studies took advantage of cell culture- 
adaptive NS3- NS5B substitutions that previously permitted 
the development of an efficient infectious culture system 
of DBN3a [12]. This is a novel approach, since most previ-
ously developed SGRs depended on mutations selected for 
enhanced HCV RNA replication [30, 31], mutations that in 
some cases are detrimental for HCV infectivity [32]. Since cell 
culture infectious systems depending on adaptive replicase 
substitutions have been developed for several HCV geno-
types [33], the approach used here could potentially benefit 
the development of robust SGRs for other HCV strains and 
genotypes.
One application of the SGR system generated here is to 
facilitate functional studies of NS5A. As proof of principle, 
we addressed the phosphorylation status of DBN3a NS5A. In 
this regard the potential function of NS5A phosphorylation 
remains enigmatic, although a number of recent studies have 
identified both sites of phosphorylation and the phenotypes 
of mutations at these sites [20, 34, 35]. These studies have 
focused on the GT2a isolate, JFH-1, and there is a dearth of 
information regarding NS5A phosphorylation in other GTs 
[18]. We show here that DBN3a NS5A exhibits both hyper- 
and basally phosphorylated forms by Western blot (Fig. 4). 
However, compared to JFH-1, there was a lower propor-
tion of the hyper- phosphorylated form, which was reactive 
with antibodies to both phospho- S225 and phospho- S232, 
consistent with the conservation of the sequence within 
LCSI. During this experiment we noted that DBN3a NS5A 
species were less clearly defined by Western blot compared 
to JFH-1, possibly indicative of some other post- translational 
modifications, which should be addressed in future studies, 
including mass spectrometry analysis of NS5A. It will also be 
of interest to determine whether DBN3a NS5A mediates an 
increase in phosphatidylinositol 4- phosphate (PI4P) lipids in 
SGR- harbouring cells. In the context of the S52 GT3a isolate, 
the acquisition of culture- adaptive mutations (including 
S2204I) resulted in a loss of PI4P induction [22], which did 
not appear to correlate with the presence or absence of the 
hyper- phosphorylated NS5A species.
GT3 infections are responsible for 30 % of HCV infections 
globally and, importantly with regard to future reduction in 
HCV burden, GT3 is associated far more often with failure 
of treatment due to RAS compared to other GTs [4]. The 
DBN3a SGR described here will be of utility in elucidating the 
molecular basis for the high level of DAA resistance of GT3. 
As proof of principle, we engineered two well- characterized 
RASs (ΔP32 and Y93H) into SGR- luc- DBN3a. Although 
ΔP32 has been observed in GT1 and indeed is a potent driver 
of DAA resistance [26, 27], it has not yet been found in any 
clinical GT3 isolates. The reason for this could be related 
to our observation that this mutation caused a significant 
decrease in the replicative fitness of SGR- luc- DBN3a (Fig. 5). 
This again may point to a critical functional role of P32 that 
is GT- specific and allude to a biological difference between 
GT3 NS5A and other GTs.
In contrast, Y93H only displayed a modest, but significant, 
effect on SGR- luc- DBN3a replication and, as expected, 
resulted in a high level resistance to the NS5A- targeted 
DAAs, DCV and VEL (4200- and 90- fold, respectively). Of 
note, this study confirmed the pan- genotypic activity of VEL; 
even Y93H DBN3a replication was effectively inhibited at 
picomolar levels, consistent with clinically attainable concen-
trations [7]. In contrast, DCV, which was previously used in 
the treatment of HCV, would most likely not inhibit Y93H 
DBN3a clinically, as concentrations 1000- fold higher than for 
VEL were needed in vitro (Fig. 6). As mentioned, the DBN3a 
SGR was more sensitive to DAAs than the corresponding 
infectious clone, particularly for the NS5A- targeting DAAs 
(10–20- fold). The reasons for this difference are unclear, as the 
opposite effect was originally observed for GT2a (JFH-1) [36]. 
It may be indicative of functional and structural differences 
between the NS5A protein of the two GTs and merits further 
investigation. It is also noteworthy that the assay systems differ 
for infectious virus and SGRs, with the former measuring the 
number of infected cells, rather than luciferase activity.
In summary, we have shown improved tools for the study 
of GT3, with the modernization of existing systems to allow 
more detailed scrutiny of replication. The use of HCV repli-
case with infectious cell culture- adaptive mutations could 
pave the way for the development of robust SGRs of other 
HCV genotypes. We report key differences in GT2 and GT3 
replication, with a delay in GT3 reporter expression and 
differences in the phosphorylation and DAA sensitivity of 
Table 1. EC
50








Cyclosporin A 389 nM 408 nM 300 nM nd
Sofosbuvir 124 nM 127 nM 177 nM 885 nM
Daclatasvir 37 pM 156 nM 20 pM 345 pM
Velpatasvir 1.3 pM 118 pM 17 pM 24 pM
* Taken from [12]. nd, not determined.
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NS5A. The robust SGRs developed here will be of utility in 
dissecting both the high level of DAA resistance and differ-
ences in clinical outcomes observed with GT3.
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